{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:51:39Z","timestamp":1790603499024,"version":"4.1.0"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"4","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Estrogen effects in tissue are mediated in part through activation of the surface estrogen receptor G protein\u2013coupled estrogen receptor (GPER), a broadly expressed G protein\u2013coupled receptor that affects a wide range of normal and pathologic processes, including metabolism, vascular health, inflammation, and cancer. A commonly used synthetic and specific GPER agonist, named G-1, antagonizes tumors by promoting cellular differentiation and enhancing tumor immunogenicity. G-1 is a racemic compound, and since its discovery, the question of whether both enantiomers display agonist activity or the agonist activity resides primarily in a single enantiomer has never been fully resolved. Herein, we disclose the isolation of the pure enantiomers of G-1 and determine that the desirable activity resides exclusively in one enantiomer, named LNS8801, whose configuration we have unambiguously determined by single-crystal X-ray structure analysis. Using preclinical models, we show that LNS8801 suppresses cancer in a GPER-dependent manner and that LNS8801 is efficacious when administered orally. Furthermore, we show that GPER is widely, but not ubiquitously, expressed in both normal and malignant human tissues. In addition, an attenuated response to LNS8801 is observed in a common germline coding variant in human GPER. These findings support ongoing human cancer trials with LNS8801 and suggest that the germline GPER genotype may serve as a predictive biomarker of therapeutic response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>GPER is broadly expressed in human tissues and has tumor-suppressive activity. No FDA-approved agents selectively target GPER. LNS8801 is a synthetic, orally bioavailable, enantiomerically pure, GPER agonist with potent anticancer activity in vivo. LNS8801 response is attenuated by a common germline coding variant present in roughly half of humans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0632","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T07:45:52Z","timestamp":1741679152000},"page":"556-568","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["LNS8801: An Enantiomerically Pure Agonist of the G Protein\u2013Coupled Estrogen Receptor Suitable for Clinical Development"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-3849","authenticated-orcid":false,"given":"Christopher A.","family":"Natale","sequence":"first","affiliation":[{"name":"1Linnaeus Therapeutics, Haddonfield, New Jersey."},{"name":"2Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0504-493X","authenticated-orcid":false,"given":"Sophia","family":"Mercado","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7256-8517","authenticated-orcid":false,"given":"Richard","family":"Zhuang","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9074-8386","authenticated-orcid":false,"given":"Cristina","family":"Aguirre-Portol\u00e9s","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0082-1522","authenticated-orcid":false,"given":"Israel","family":"Olayide","sequence":"additional","affiliation":[{"name":"3Department of Chemistry and Biochemistry, Saint Louis University, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9445-4796","authenticated-orcid":false,"given":"Christopher K.","family":"Arnatt","sequence":"additional","affiliation":[{"name":"3Department of Chemistry and Biochemistry, Saint Louis University, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0383-031X","authenticated-orcid":false,"given":"John T.","family":"Seykora","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9465-1976","authenticated-orcid":false,"given":"Tina K.","family":"Garyantes","sequence":"additional","affiliation":[{"name":"1Linnaeus Therapeutics, Haddonfield, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8607-2357","authenticated-orcid":false,"given":"Wayne","family":"Luke","sequence":"additional","affiliation":[{"name":"1Linnaeus Therapeutics, Haddonfield, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8482-1284","authenticated-orcid":false,"given":"Todd W.","family":"Ridky","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"2025051309034097800_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41574-023-00822-7","article-title":"The G protein-coupled oestrogen receptor GPER in health and disease: an update","volume":"19","author":"Prossnitz","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"2025051309034097800_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev-pharmtox-031122-121944","article-title":"G protein\u2013coupled estrogen receptor GPER: molecular pharmacology and therapeutic applications","volume":"63","author":"Arterburn","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2025051309034097800_bib3","doi-asserted-by":"crossref","first-page":"e31770","DOI":"10.7554\/eLife.31770","article-title":"Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade","volume":"7","author":"Natale","year":"2018","journal-title":"Elife"},{"key":"2025051309034097800_bib4","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jcmgh.2020.04.016","article-title":"Pharmacologic activation of the G protein\u2013coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma","volume":"10","author":"Natale","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2025051309034097800_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrd3859","article-title":"The GPCR Network: a large-scale collaboration to determine human GPCR structure and function","volume":"12","author":"Stevens","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"2025051309034097800_bib6","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/1055-9965.EPI-08-1118","article-title":"Sex disparities in cancer incidence by period and age","volume":"18","author":"Cook","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025051309034097800_bib7","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1055-9965.EPI-11-0246","article-title":"Sex disparities in cancer mortality and survival","volume":"20","author":"Cook","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025051309034097800_bib8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJM195904162601601","article-title":"Studies on melanoma. II. Sex and survival in human melanoma","volume":"260","author":"White","year":"1959","journal-title":"N Engl J Med"},{"key":"2025051309034097800_bib9","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/S1470-2045(18)30483-2","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025051309034097800_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10552-005-0281-y","article-title":"Pregnancy history and incidence of melanoma in women: a pooled analysis","volume":"17","author":"Karagas","year":"2006","journal-title":"Cancer Causes Control"},{"key":"2025051309034097800_bib11","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1200\/JCO.2012.44.5031","article-title":"Sex is an independent prognostic indicator for survival and relapse\/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials","volume":"31","author":"Joosse","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025051309034097800_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/1097-0142(197707)40:1<389::AID-CNCR2820400155>3.0.CO;2-I","article-title":"Prognosis in malignant melanoma of the skin. Significance of stage of disease, anatomical site, sex, age and period of diagnosis","volume":"40","author":"Magnus","year":"1977","journal-title":"Cancer"},{"key":"2025051309034097800_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(77)91943-2","article-title":"Previous pregnancy as a protective factor against death from melanoma","volume":"1","author":"Hersey","year":"1977","journal-title":"Lancet"},{"key":"2025051309034097800_bib14","first-page":"415","article-title":"Cancer mortality among males and females in Denmark, England, and Switzerland; incidence of accessible and inaccessible cancers in Danish towns and rural areas","volume":"9","author":"Clemmesen","year":"1949","journal-title":"Cancer Res"},{"key":"2025051309034097800_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nchembio775","article-title":"Virtual and biomolecular screening converge on a selective agonist for GPR30","volume":"2","author":"Bologa","year":"2006","journal-title":"Nat Chem Biol"},{"key":"2025051309034097800_bib16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.tem.2009.04.006","article-title":"GPR30\/GPER1: searching for a role in estrogen physiology","volume":"20","author":"Olde","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"2025051309034097800_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1089\/dna.2016.3235","article-title":"Activation of G-protein-coupled estrogen receptor inhibits the migration of human nonsmall cell lung cancer cells via IKK-\u03b2\/NF-\u03baB signals","volume":"35","author":"Zhu","year":"2016","journal-title":"DNA Cell Biol"},{"key":"2025051309034097800_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12943-017-0654-3","article-title":"Epigenetic down regulation of G protein-coupled estrogen receptor (GPER) functions as a tumor suppressor in colorectal cancer","volume":"16","author":"Liu","year":"2017","journal-title":"Mol Cancer"},{"key":"2025051309034097800_bib19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/jdv.14304","article-title":"Expression of G protein-coupled oestrogen receptor in melanoma and in pregnancy-associated melanoma","volume":"31","author":"F\u00e1bi\u00e1n","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025051309034097800_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jneuroim.2009.06.023","article-title":"Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis","volume":"214","author":"Blasko","year":"2009","journal-title":"J Neuroimmunol"},{"key":"2025051309034097800_bib21","article-title":"Enantiomerically purified GPER agonist for use in treating disease states and conditions","author":"Natale","year":"2023"},{"key":"2025051309034097800_bib22","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/minf.201200136","article-title":"G protein-coupled estrogen receptor (GPER) agonist dual binding mode analyses toward understanding of its activation mechanism: a comparative homology modeling approach","volume":"32","author":"Arnatt","year":"2013","journal-title":"Mol Inform"},{"key":"2025051309034097800_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1126\/science.1246981","article-title":"Genetic screens in human cells using the CRISPR-Cas9 system","volume":"343","author":"Wang","year":"2014","journal-title":"Science"},{"key":"2025051309034097800_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.cels.2016.04.011","article-title":"Simultaneous pathway activity inference and gene expression analysis using RNA sequencing","volume":"2","author":"O\u2019Connell","year":"2016","journal-title":"Cell Syst"},{"key":"2025051309034097800_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"2025051309034097800_bib26","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1039\/c001307b","article-title":"Highly efficient synthesis and characterization of the GPR30-selective agonist G-1 and related tetrahydroquinoline analogs","volume":"8","author":"Burai","year":"2010","journal-title":"Org Biomol Chem"},{"key":"2025051309034097800_bib27","doi-asserted-by":"crossref","first-page":"e15104","DOI":"10.7554\/eLife.15104","article-title":"Sex steroids regulate skin pigmentation through nonclassical membrane-bound receptors","volume":"5","author":"Natale","year":"2016","journal-title":"Elife [Internet]"},{"key":"2025051309034097800_bib28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/acsmedchemlett.8b00212","article-title":"A series of indole-thiazole derivatives act as GPER agonists and inhibit breast cancer cell growth","volume":"9","author":"O\u2019Dea","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"2025051309034097800_bib29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1210\/mend.16.1.0758","article-title":"Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis","volume":"16","author":"Filardo","year":"2002","journal-title":"Mol Endocrinol"},{"key":"2025051309034097800_bib30","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/bcp.12471","article-title":"A common hypofunctional genetic variant of GPER is associated with increased blood pressure in women","volume":"78","author":"Feldman","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2025051309034097800_bib31","doi-asserted-by":"crossref","first-page":"46728","DOI":"10.18632\/oncotarget.18156","article-title":"A genetic polymorphism repurposes the G-protein coupled and membrane-associated estrogen receptor GPER to a transcription factor-like molecule promoting paracrine signaling between stroma and breast carcinoma cells","volume":"8","author":"Pupo","year":"2017","journal-title":"Oncotarget"},{"key":"2025051309034097800_bib32","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.3390\/ijms23095191","article-title":"Assessment of G protein-coupled oestrogen receptor expression in normal and neoplastic human tissues using a novel rabbit monoclonal antibody","volume":"23","author":"Bubb","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025051309034097800_bib33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jsbmb.2011.07.002","article-title":"Identification of a GPER\/GPR30 antagonist with improved estrogen receptor counterselectivity","volume":"127","author":"Dennis","year":"2011","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2025051309034097800_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.steroids.2013.10.017","article-title":"Vasodilation by GPER in mesenteric arteries involves both endothelial nitric oxide and smooth muscle cAMP signaling","volume":"81","author":"Lindsey","year":"2014","journal-title":"Steroids"},{"issue":"suppl","key":"2025051309034097800_bib35","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2021.39.15_suppl.3084","article-title":"Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies","volume":"39","author":"Muller","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2025051309034097800_bib36","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1200\/JCO.2022.40.16_suppl.2574","article-title":"Phase 1b study of the novel first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-relapsed and refractory solid malignancies and dose escalation update","volume":"40","author":"Muller","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025051309034097800_bib37","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/ijms20020306","article-title":"G-protein coupled estrogen receptor in breast cancer","volume":"20","author":"Hsu","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025051309034097800_bib38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fendo.2014.00066","article-title":"GPER function in breast cancer: an overview","volume":"5","author":"Lappano","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025051309034097800_bib39","doi-asserted-by":"crossref","first-page":"e1428","DOI":"10.1038\/cddis.2014.398","article-title":"The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo","volume":"5","author":"Wei","year":"2014","journal-title":"Cell Death Dis"},{"key":"2025051309034097800_bib40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00432-014-1598-2","article-title":"GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells","volume":"140","author":"Wei\u00dfenborn","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025051309034097800_bib41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00432-014-1620-8","article-title":"GPER functions as a tumor suppressor in triple-negative breast cancer cells","volume":"140","author":"Weissenborn","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025051309034097800_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10549-014-2936-4","article-title":"Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer","volume":"145","author":"Sj\u00f6str\u00f6m","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2025051309034097800_bib43","doi-asserted-by":"crossref","first-page":"25946","DOI":"10.18632\/oncotarget.25408","article-title":"Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients","volume":"9","author":"Martin","year":"2018","journal-title":"Oncotarget"},{"issue":"suppl","key":"2025051309034097800_bib44","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1200\/JCO.2023.41.16_suppl.9543","article-title":"The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma","volume":"41","author":"Shoushtari","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025051309034097800_bib45","doi-asserted-by":"crossref","first-page":"S746","DOI":"10.1016\/j.annonc.2024.08.2140","article-title":"1137P Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors","volume":"35","author":"Cohen","year":"2024","journal-title":"Ann Oncol"},{"key":"2025051309034097800_bib46","doi-asserted-by":"crossref","first-page":"S663","DOI":"10.1016\/j.annonc.2023.09.2235","article-title":"1101P the effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma","volume":"34","author":"Rodon","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0632\/3556656\/crc-24-0632.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/4\/556\/3566538\/crc-24-0632.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/4\/556\/3566538\/crc-24-0632.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T09:03:59Z","timestamp":1747127039000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/4\/556\/754636\/LNS8801-An-Enantiomerically-Pure-Agonist-of-the-G"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0632","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29051147","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28730211","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28730187","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051159","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28730199","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28730196","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28730184","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051150","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28730193","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28730190","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051153","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051156","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051144","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28730208","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28730217","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28730205","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28730214","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28730202","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7754034","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/2024.11.26.625421","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}